Ironwood Poised To Move Linaclotide To Phase III In IBS-C
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.
You may also be interested in...
Strong Phase III Data Have Linaclotide On Track For Filing In 2011
Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.
Strong Phase III Data Have Linaclotide On Track For Filing In 2011
Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.
Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.